You are here: Industry Insights > leukaemia drug

News List

FDA halts Xencor’s study of XmAb14045 following deaths pharmaceutical-technology
February 22, 2019
California-based Xencor has announced the US Food and Drug Administration (FDA) has placed a partial clinical hold on its Phase I trial of its acute myeloid leukaemia drug XmAb14045 following the deaths of two participants....
Innate Pharma gains rights to AZ’s recently approved leukaemia drug pharmaphorum
December 21, 2018
France’s Innate Pharma has gained rights to AstraZeneca’s recently approved leukaemia drug Lumoxiti, in a deal that expands a collaboration that began more than three years ago.
The curious case of Mylotarg: Pfizer’s leukaemia drug set to return pharmaphorum
July 13, 2017
Pfizer’s Mylotarg looks set for a return to the US market after FDA advisers recommended its use in acute myeloid leukaemia.
Pfizer facing NICE showdown over leukaemia drug pharmaphorum
July 05, 2017
Pfizer’s Besponsa leukaemia drug has been approved in Europe, but the company is heading for a showdown with England’s NICE, which has said in a draft decision that the medicine it is too expensive for regular NHS funding.
NICE does not recommend AbbVie’s leukaemia drug europeanpharmaceuticalreview
February 17, 2017
The National Institute for Health and Care Excellence (NICE) has published draft guidance that does not recommend venetoclax (Venclyxto, AbbVie) within its marketing authorisation for treating chronic lymphocytic leukaemia.
NICE approves Incyte’s leukaemia drug for routine NHS use europeanpharmaceuticalreview
February 14, 2017
The National Institute for Health and Care Excellence (NICE) published draft guidance recommending ponatinib (Iclusig, Incyte Corporation) for routine use on the NHS, to treat some patients with chronic myeloid leukaemia and acute lymphoblastic leukaemia.